Colchicine plus Dapsone in Colchicine‐Resistant FMF Patients
Five to ten percent of FMF patients have unfavorable response to the colchicine as a standard therapy. Biologic treatments have been shown to be highly effective, but there are often unavailable, because the price is unaffordably high. This study shows the striking effect of combined dapsone and col...
Saved in:
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Case Reports in Rheumatology |
Online Access: | http://dx.doi.org/10.1155/2019/2716127 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832552345933709312 |
---|---|
author | Farhad Salehzadeh A. Enteshary M. Moshkbar |
author_facet | Farhad Salehzadeh A. Enteshary M. Moshkbar |
author_sort | Farhad Salehzadeh |
collection | DOAJ |
description | Five to ten percent of FMF patients have unfavorable response to the colchicine as a standard therapy. Biologic treatments have been shown to be highly effective, but there are often unavailable, because the price is unaffordably high. This study shows the striking effect of combined dapsone and colchicine therapy in such patients and recommends it as an alternative therapy in colchicine-resistant (CR) patients. |
format | Article |
id | doaj-art-304be31df1eb46ed8c3f9b25551540f7 |
institution | Kabale University |
issn | 2090-6889 2090-6897 |
language | English |
publishDate | 2019-01-01 |
publisher | Wiley |
record_format | Article |
series | Case Reports in Rheumatology |
spelling | doaj-art-304be31df1eb46ed8c3f9b25551540f72025-02-03T05:58:53ZengWileyCase Reports in Rheumatology2090-68892090-68972019-01-01201910.1155/2019/27161272716127Colchicine plus Dapsone in Colchicine‐Resistant FMF PatientsFarhad Salehzadeh0A. Enteshary1M. Moshkbar2Professor in Pediatric Rheumatology, Pediatric Department, Bouali Children’s Hospital, Ardabil University of Medical Sciences (ARUMS), Ardabil, IranAssistant Professor of Rheumatology, Internal Medicine Department, Imam Khomeini Hospital, Ardabil University of Medical Sciences (ARUMS), Ardabil, IranPediatric Department, Bouali Children’s Hospital, Ardabil University of Medical Sciences (ARUMS), Ardabil, IranFive to ten percent of FMF patients have unfavorable response to the colchicine as a standard therapy. Biologic treatments have been shown to be highly effective, but there are often unavailable, because the price is unaffordably high. This study shows the striking effect of combined dapsone and colchicine therapy in such patients and recommends it as an alternative therapy in colchicine-resistant (CR) patients.http://dx.doi.org/10.1155/2019/2716127 |
spellingShingle | Farhad Salehzadeh A. Enteshary M. Moshkbar Colchicine plus Dapsone in Colchicine‐Resistant FMF Patients Case Reports in Rheumatology |
title | Colchicine plus Dapsone in Colchicine‐Resistant FMF Patients |
title_full | Colchicine plus Dapsone in Colchicine‐Resistant FMF Patients |
title_fullStr | Colchicine plus Dapsone in Colchicine‐Resistant FMF Patients |
title_full_unstemmed | Colchicine plus Dapsone in Colchicine‐Resistant FMF Patients |
title_short | Colchicine plus Dapsone in Colchicine‐Resistant FMF Patients |
title_sort | colchicine plus dapsone in colchicine resistant fmf patients |
url | http://dx.doi.org/10.1155/2019/2716127 |
work_keys_str_mv | AT farhadsalehzadeh colchicineplusdapsoneincolchicineresistantfmfpatients AT aenteshary colchicineplusdapsoneincolchicineresistantfmfpatients AT mmoshkbar colchicineplusdapsoneincolchicineresistantfmfpatients |